Posted by Michael Wonder on 20 Sep 2022
NICE recommends BeiGene’s Brukinsa (zanubrutinib) for patients with Waldenström’s macroglobulinaemia who have had at least one treatment
19 September 2022 - Brukinsa Is the first Bruton’s tyrosine kinase inhibitor recommended by NICE for routine use for Waldenström’s macroglobulinaemia.
BeiGene today announced that England’s NICE, has issued a final appraisal document recommending Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinaemia in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable.
